Independent of EGFR-mediated MAPK/AKT signaling, PKM phosphorylation was highly ranked in approximately half of our ccRCC tumor cohort and associated with lower tumor grade (p < 0.05) (Figures 5A and S5B), reflecting a secondary, EGFR-mediated mechanism of glycolytic reprogramming in a subset of ccRCC tumors (Lim et al., 2016). The gene discussed is AKT1; the disease is nonpapillary renal cell carcinoma.